Filtering by
- All Subjects: trauma
- All Subjects: Food and Drug Administration
- Creators: Pizziconi, Vincent
- Resource Type: Text
The purpose of this study is to collect baseline internal and external pressure data for the three most commonly used pelvic circumferential compression devices (PCCD). Unstable pelvic fractures as a result of automobile accidents, falls, and other traumatic injuries mortality rate [3]. Early use of pelvic circumferential compression devices can mitigate fatal outcomes [4]-[5]. Prolonged eternal pressure above 9.3kPa can result in long-term soft tissue damage and pressure ulcers [7]. This study hypothesizes that the application of the three most commonly used PCCDs would result in the same mean maximum point pressure exertion. To study this, internal and external, both analog and digital, pressure apparati were used to collect data. The results of this data collection demonstrate a discrepancy in the pressure distribution between right and left greater trochanters within each PCCD. Additionally, the results suggest there is an effect of internal packing on the pressure exertion externally at the two greater trochanters within each PCCD. Lastly, the differences in pressure exertion between each PCCD, internally and externally, were inconclusive as some compared metrics resulted in statistically significant results while others did not. The methodologies employed in this study can be improved through fixation of pressure collection instruments, utilization of digital pressure mats, and removal of confounding factors. The results of this study indicate that digitized, discrete data over a fixed time interval may be clinically useful, suggesting that a digital data collection would yield more reliable data. Additionally, internally mounted pressure sensor data will provide more precise results than the analog method employed herein, as well as provide insight towards bone reduction and displacement following the application of PCCDs. Finally, the information gathered from this study can be utilized to improve upon existing technologies to create a more innovative solution.
The purpose of this study is to collect baseline internal and external pressure data for the three most commonly used pelvic circumferential compression devices (PCCD). Unstable pelvic fractures as a result of automobile accidents, falls, and other traumatic injuries mortality rate [3]. Early use of pelvic circumferential compression devices can mitigate fatal outcomes [4]-[5]. Prolonged eternal pressure above 9.3kPa can result in long-term soft tissue damage and pressure ulcers [7]. This study hypothesizes that the application of the three most commonly used PCCDs would result in the same mean maximum point pressure exertion. To study this, internal and external, both analog and digital, pressure apparati were used to collect data. The results of this data collection demonstrate a discrepancy in the pressure distribution between right and left greater trochanters within each PCCD. Additionally, the results suggest there is an effect of internal packing on the pressure exertion externally at the two greater trochanters within each PCCD. Lastly, the differences in pressure exertion between each PCCD, internally and externally, were inconclusive as some compared metrics resulted in statistically significant results while others did not. The methodologies employed in this study can be improved through fixation of pressure collection instruments, utilization of digital pressure mats, and removal of confounding factors. The results of this study indicate that digitized, discrete data over a fixed time interval may be clinically useful, suggesting that a digital data collection would yield more reliable data. Additionally, internally mounted pressure sensor data will provide more precise results than the analog method employed herein, as well as provide insight towards bone reduction and displacement following the application of PCCDs. Finally, the information gathered from this study can be utilized to improve upon existing technologies to create a more innovative solution.
Brave Bears was a Barrett creative project that operated under local non-profit organizations, Amanda Hope Rainbow Angels and Arizona Women’s Recovery Center. Amanda Hope Rainbow Angels provides support and education for children fighting cancer and their families. Arizona Women’s Recovery Center provides rehabilitation programs for women fighting substance abuse and housing for the women and their children. The Brave Bears Project was focused on helping children in these situations cope with the trauma they are experiencing. The children received a teddy bear, which is a transitional object. In addition, a clay pendant with the word, “brave” pressed into it was tied around the bear’s neck with a ribbon. A poem of explanation and encouragement was also included.<br/><br/>The teddy bear provided comfort to children experiencing emotionally distressing situations as they receive treatment for their illness or as their mom undergoes rehabilitation. This can be in the form of holding the teddy bear when they feel frightened, anxious, lonely or depressed. The “brave” pendant and poem seek to encourage them and acknowledge their trauma and ability to persevere.
In 2015, the FDA began a process to reevaluate and update the regulations surrounding homeopathic products to better fit their present risk-based model. Past regulations were set in 1938; and as the world evolved, these have been found to set inadequate standards. By reviewing the agency’s guidance drafts and core regulatory documents, we come to understand that these changes are motivated by a desire for homeopathic remedies to follow high standards that apply to other products for the benefit of the U.S. consumers. FDA has made significant advances by proposing new Guidances on homeopathic products, listening to homeopathic community and consumers, and withdrawing the Compliance Policy Guide 400.400 issued in 1988.
We recommend for homeopathic manufacturers and practitioners to see the FDA as an ally and cooperate fully with the proposed changes for the regulation the agency gives out. Doing so will give the homeopathic community the best chance at continuing to sell their products and reach their consumers in the United States. In the same token, the FDA should do their best to involve homeopathic professionals in some way in this regulatory process, to encourage participation and compliance by the broader homeopathic community. Doing so ensures a climate of teamwork among different facets of the medical community in the United States.